CRESCENT BIOPHARMA, INC. Lease, Cost
CRESCENT BIOPHARMA, INC. (CBIO) reported Lease, Cost of $367.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-02-26
- CRESCENT BIOPHARMA, INC. lease, cost for the quarter ending 2025-03-31 was $30.37K, a 89.46% decline year-over-year.
- CRESCENT BIOPHARMA, INC. lease, cost for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- CRESCENT BIOPHARMA, INC. lease, cost for the quarter ending 2024-09-30 was $207.52K, a 49.46% decline year-over-year.
- CRESCENT BIOPHARMA, INC. lease, cost for the quarter ending 2024-06-30 was $327.13K, a 14.00% decline year-over-year.
- CRESCENT BIOPHARMA, INC. lease, cost for fiscal 2025 was $367.00K, a 62.03% decline from fiscal 2024.
- CRESCENT BIOPHARMA, INC. lease, cost for fiscal 2024 was $966.62K, a 37.53% decline from fiscal 2023.
- CRESCENT BIOPHARMA, INC. lease, cost for fiscal 2023 was $1.55M, a 0.46% increase from fiscal 2022.
- CRESCENT BIOPHARMA, INC. lease, cost for fiscal 2022 was $1.54M, a 8.56% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $367.00K 10-K · filed 2026-02-26 | ||||
| 2025-03-31 | $30.37K 10-Q · filed 2025-05-14 | $30.37K derived: sum of 2 quarters · filed 2026-02-26 | $237.89K derived: sum of 3 quarters · filed 2026-02-26 | $565.02K derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | $207.52K derived: sum of 2 quarters · filed 2026-02-26 | $534.65K derived: sum of 3 quarters · filed 2026-02-26 | $966.62K 10-K · filed 2025-02-13 | |
| 2024-09-30 | $207.52K 10-Q · filed 2024-11-13 | $534.65K derived: sum of 2 quarters · filed 2024-11-13 | $822.85K 10-Q · filed 2024-11-13 | $1.16M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-06-30 | $327.13K 10-Q · filed 2024-08-08 | $615.33K 10-Q · filed 2024-08-08 | $956.43K derived: sum of 3 quarters · filed 2025-05-14 | $1.37M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-03-31 | $288.20K 10-Q · filed 2025-05-14 | $629.30K derived: sum of 2 quarters · filed 2025-05-14 | $1.04M derived: sum of 3 quarters · filed 2025-05-14 | $1.42M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $341.11K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $751.73K derived: sum of 2 quarters · filed 2025-02-13 | $1.13M derived: sum of 3 quarters · filed 2025-02-13 | $1.55M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $410.63K 10-Q · filed 2024-11-13 | $791.01K derived: sum of 2 quarters · filed 2024-11-13 | $1.21M 10-Q · filed 2024-11-13 | $1.59M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $380.38K 10-Q · filed 2024-08-08 | $795.64K 10-Q · filed 2024-08-08 | $1.18M derived: sum of 3 quarters · filed 2024-08-08 | $1.57M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $415.26K 10-Q · filed 2023-05-03 | $801.00K derived: sum of 2 quarters · filed 2024-03-27 | $1.19M derived: sum of 3 quarters · filed 2024-03-27 | $1.57M derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-12-31 | $385.74K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $771.48K derived: sum of 2 quarters · filed 2024-03-27 | $1.16M derived: sum of 3 quarters · filed 2024-03-27 | $1.54M 10-K · filed 2024-03-27 | |
| 2022-09-30 | $385.74K 10-Q · filed 2023-11-03 | $771.48K derived: sum of 2 quarters · filed 2023-11-03 | $1.15M 10-Q · filed 2023-11-03 | $1.53M derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-06-30 | $385.74K 10-Q · filed 2023-08-02 | $768.86K 10-Q · filed 2023-08-02 | $1.15M derived: sum of 3 quarters · filed 2024-03-27 | $1.53M derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-03-31 | $383.12K 10-Q · filed 2023-05-03 | $761.53K derived: sum of 2 quarters · filed 2024-03-27 | $1.14M derived: sum of 3 quarters · filed 2024-03-27 | $1.42M derived: sum of 4 quarters · filed 2024-03-27 | |
| 2021-12-31 | $378.41K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $756.82K derived: sum of 2 quarters · filed 2024-03-27 | $1.04M derived: sum of 3 quarters · filed 2024-03-27 | $1.42M 10-K · filed 2024-03-27 | $1.42B 10-K · filed 2022-03-03 |
| 2021-09-30 | $378.41K 10-Q · filed 2022-11-09 | $662.01K derived: sum of 2 quarters · filed 2022-11-09 | $1.04M 10-Q · filed 2022-11-09 | $1.42M derived: sum of 4 quarters · filed 2023-03-29 | |
| 2021-06-30 | $283.60K 10-Q · filed 2022-08-03 | $662.01K 10-Q · filed 2022-08-03 | $1.04M derived: sum of 3 quarters · filed 2023-03-29 | $1.41M derived: sum of 4 quarters · filed 2023-03-29 | |
| 2021-03-31 | $378.41K 10-Q · filed 2022-04-28 | $754.41K derived: sum of 2 quarters · filed 2023-03-29 | $1.13M derived: sum of 3 quarters · filed 2023-03-29 | $1.51M derived: sum of 4 quarters · filed 2023-03-29 | |
| 2020-12-31 | $376.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $752.00K derived: sum of 2 quarters · filed 2023-03-29 | $1.13M derived: sum of 3 quarters · filed 2023-03-29 | $1.52M 10-K · filed 2023-03-29 | |
| 2020-09-30 | $376.00K 10-Q · filed 2021-11-02 | $752.00K derived: sum of 2 quarters · filed 2021-11-02 | $1.15M 10-Q · filed 2021-11-02 | $1.39B derived: sum of 4 quarters · filed 2022-03-03 | |
| 2020-06-30 | $376.00K 10-Q · filed 2021-08-05 | $769.93K 10-Q · filed 2021-08-05 | $1.39B derived: sum of 3 quarters · filed 2022-03-03 | $1.39B derived: sum of 4 quarters · filed 2022-03-03 | |
| 2020-03-31 | $393.94K 10-Q · filed 2021-05-03 | $1.39B derived: sum of 2 quarters · filed 2022-03-03 | $1.39B derived: sum of 3 quarters · filed 2022-03-03 | $1.39B derived: sum of 4 quarters · filed 2022-03-03 | |
| 2019-12-31 | $1.39B derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $1.39B derived: sum of 2 quarters · filed 2022-03-03 | $1.39B derived: sum of 3 quarters · filed 2022-03-03 | $1.39B 10-K · filed 2022-03-03 | $1.39M 10-K · filed 2020-02-28 |
| 2019-09-30 | $380.34K 10-Q · filed 2020-11-06 | $697.10K derived: sum of 2 quarters · filed 2020-11-06 | $1.02M 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $316.76K 10-Q · filed 2020-07-31 | $640.51K 10-Q · filed 2020-07-31 | |||
| 2019-03-31 | $323.75K 10-Q · filed 2020-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |